Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
72.64
+1.08 (1.51%)
Oct 29, 2025, 11:09 AM EDT - Market open
Corcept Therapeutics Employees
Corcept Therapeutics had 500 employees as of December 31, 2024. The number of employees increased by 148 or 42.05% compared to the previous year.
Employees
500
Change (1Y)
148
Growth (1Y)
42.05%
Revenue / Employee
$1,432,160
Profits / Employee
$264,022
Market Cap
7.65B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 500 | 148 | 42.05% |
| Dec 31, 2023 | 352 | 53 | 17.73% |
| Dec 31, 2022 | 299 | 61 | 25.63% |
| Dec 31, 2021 | 238 | 2 | 0.85% |
| Dec 31, 2020 | 236 | 30 | 14.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CORT News
- 19 hours ago - Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 10 days ago - Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment - Business Wire
- 14 days ago - Corcept Transition To New Specialty Pharmacy Well Underway - Seeking Alpha
- 15 days ago - Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 4 weeks ago - Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics - Business Wire
- 4 weeks ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 4 weeks ago - Corcept Primed For An Upside EPS Surprise - Seeking Alpha
- 5 weeks ago - Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025 - Business Wire